Syncytia formation during SARS-CoV-2 lung infection: a disastrous unity to eliminate lymphocytes.

Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, has become a major threat to the global public health and economy [1, 2]. While the majorities of SARS-CoV-2 infected individuals only suffer mild or moderate symptoms, unfortunately, some patients develop severe chronic respiratory diseases (CRDs) and have to be admitted to intensive care units [3, 4]. When the lungs of CRDs patients were analyzed histologically, many of them possess multinucleate pneumocytes. Two independent studies from the Mauro Giacca group and the Qiang Sun group, which were just published in Nature and Cell Death and Differentiation, provided critical insights into the causes and consequences of syncytia during SARS-CoV-2 infections [5, 6].

Syncytia are evolutionarily conserved cellular structures form by the multiple cell fusions of uninuclear cells. In mammals, the best example of physiological syncytia is muscle fibers, which contain thousands of fused muscle cells to allows their rapid coordinated contraction [7]. It is also important in the decidualization process during embryo implantation [8]. Syncytia can also be induced by certain types of infections by viruses, such as human immunodeficiency virus, respiratory syncytial virus, and herpes simplex virus [9]. It could be envisioned that virus-induced cell fusion facilitates the transfer of viral genomes to the neighboring cells. However, the viral and cellular mechanisms regulating the formation of syncytia during SARS-CoV-2 infection remains largely elusive.

While examining the histopathologic lung sections from patients died from COVID-19, the Giacca group and the Sun group observed the prevailing existence of atypical cells containing 2-20 nuclei. The identities of these syncytia were later confirmed by their expression of pneumocyte specific makers. In vitro co-culture assay showed that monkey kidney epithelial cell line, Vero cells (ACE2+), upon expressing the SARS-CoV-2 spike protein, could form homologous syncytia or fuse with other cell lines as long as the ACE2 receptor was present. Interestingly, when Vero cells were transfected with Spike protein from SARS-CoV-1, no formation of syncytia was observed. Therefore, the key element responsible for SARS-CoV-2-mediated syncytia is absent in the spike protein of SARS-CoV-1. Driven by this hypothesis, Sun and et al. compared the spike protein from SARS-CoV-2 and SARS-CoV1 and found that there is a four amino acids (PRRA) insertion before the S1/S2 cleavage site in the SARS-CoV-2 spike protein. The truncated mutation of SARS-CoV-2 spike protein with “PRRA” deletion lose its abilities to fuse cells. Consistently, spike protein from SARS-CoV1 effectively induced syncytia once the “PRRA” sequence was inserted before the S1/S2 cleavage site of the SARS-CoV-1 genome. Furthermore, the Sun group demonstrated that a bi-arginine motif containing R682 and R685 dictates syncytium formation by constructing single or combine mutations in the “PPRA” insertion. Fig. 1.

Fig. 1

The SARS-CoV-2 spike protein and cellular TMEM16 ion channel collaboratively mediated the formation of syncytia in COVID-19 infections.

Pneumocytes infected with SARS-CoV-2 expressed the virus spike protein on their surface membrane. The bi-arginine motif (R682 and R685) in the spike protein interacted with ACE2 on health cells and activated TMEM16F, which eventually induced cell fusion. The syncytia formation on one hand facilitated virus transmission, and on the other hand, endowed multinucleate pneumocytes the abilities to engulf CD45+ cells.

The new data obtained by Sun et al. provide critical information for understanding syncytia through deciphering the structure basis required for SARS-CoV-2 spike protein-mediated cell fusion, while Giacca et al. focused on the cellular mechanism and therapeutic potential of syncytia during SARS-Cov-2 infection. In this regard, Giacca and colleagues screened 3049 FDA/EMA-approved drugs using SARS-CoV-2 spike protein expressing Vero cell-based in vitro cell fusion system to search for drugs that block syncytia. Interestingly, drugs that suppressed cell fusion are all capable of regulating intracellular Ca2+ levels. Among the syncytia blocking drugs, niclosamide, an oral anti-helminthic agent, was found to be effective at a very low dose (IC50 = 0.34 μM) and could prevent cell from virus-induced cell death. Niclosamide is a potent antagonist of Ca2+-activated TMEM16/anoctamin family of chloride channels [10]. TMEM16F was also dramatically increased in Vero cells upon spike protein expression. When TMEM16F expression was disturbed, the syncytia formation in spike-expression cells were diminished. Therefore, TMEM16F activation is the signal responsible for triggering syncytia.

These two elegant studies collectively revealed a new concept of syncytia formation and its roles in SARS-CoV-2 infections, which can be briefly précised as follows. The SARS-CoV-2 infections induce the surface expression of the spike glycoprotein. The interaction of the spike protein with the ACE2 receptor of the neighboring cells then activate TMEM16F, and trigger the unshealthe of the profusion S2 fragment of the spike protein in a bi-arginine motif dependent manner, which eventually leads to the membrane fusion and syncytia formation. However, there are still many questions that remain to be elucidated. One of which is whether the bi-arginine motif is required for the activation of TMEM16F. Another is the impact of syncytia formation on SARS-CoV-2 infections in vivo. Sun et al. found that a type of CD45 positive cell structure presents in the syncytia of the COVID-19 patients. This could be a cell-in-cell structure. When human peripheral blood mononuclear cells were co-cultured with SARS-CoV-2 spike protein-induced syncytia, they could be engulfed by and die inside the syncytia, thus providing a possible explanation for lymphopenia in SARS-CoV-2 infections [11]. It can be highly suspected that syncytia are deleterious for COVID-19 patients since syncytia were observed only in the severe stages of the diseases and syncytia may induce lymphopenia. Despite the observation of multinucleate pneumocytes in autopsy, it is still not known whether such syncytia play a critical role in the pathogenesis of CRDs of severe COVID-19 patients. Recently, an antidepressant drug, fluvoxamine, was shown to lower the likelihood of clinical deterioration of severe COVID-19 patients in a randomized clinical trial [12]. Interestingly, fluvoxamine could facilitate TMEMF activation and phosphatidylserine exposure [13]. It is imperative to examine whether fluvoxamine affects syncytia formation. It is also worthy to evaluate the whether the combine uses of anti-syncytia drugs with other COVID-19 targets would yield better clinical outcomes [14, 15].

Overall, these two papers provide critical information for the understanding of how syncytia occurred during SARS-CoV-2 infections at the virus structure and cellular signaling points of views and open up a new revenue in COVID-19 studies. It is anticipated that these novel findings may provide information for developing new strategies to combat the current pandemic.

Author Contribution Form